CStone Pharmaceuticals
CSPHF
Other OTC0.70
USD
- -
- -
ISIN
KYG2588M1006
Return %
Stock
S&P500
1Y
34.17
26.84
3Y
47.87
77.03
5Y
-60.06
80.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Jianxin Yang
- Full Time Employees
- 135
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- New Bund Times Square Shanghai People's Republic of China 201203
- IPO Date
- Sep 14, 2020
- Website
- cstonepharma.com
- Similar Companies
- Business
- CStone Pharmaceuticals (CSPHF) is a biopharmaceutical company focused on developing and commercializing innovative oncology therapies. The company offers a portfolio of targeted cancer treatments including sugemalimab (Cejemly), a PD-L1 monoclonal antibody approved for stage IV non-small cell lung cancer and in combination with chemotherapy for early-stage NSCLC; CS1001 (cadonilimab), a PD-1/CTLA-4 bispecific antibody for various solid tumors; and other pipeline candidates such as CS5001 (ROR1 ADC), CS2009 (IL-12 prodrug), and CS2020 (PVRIG monoclonal antibody), spanning antibody-drug conjugates, bispecific antibodies, and immuno-oncology assets. Its products target solid tumors and hematological malignancies, serving patients through partnerships with global pharmaceutical firms. Founded in 2015 and headquartered in Suzhou, China, CStone operates primarily in Asia with expanding global reach, including approvals and commercialization in China, Australia, and Europe; the company maintains subsidiaries and collaborations across the United States, Europe, and Asia-Pacific regions. It functions in the biotechnology segment of the healthcare industry, with key customers encompassing hospitals, oncology centers, and strategic partners like Pfizer, Roche, and Fosun Pharma. In recent developments, CStone secured approval for sugemalimab (branded as Cejemly) in the U.S. through a collaboration with Pfizer in 2024, marking its first product launch outside China and Australia. The company also advanced multiple Phase III trials, including positive topline results for cadonilimab in gastric cancer, and expanded partnerships, such as with Innovent Biologics for combination therapies. Additionally, in 2024-2025, CStone restructured its leadership and financing amid market challenges, raising funds through equity offerings and optimizing its pipeline for high-priority assets.
ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept
CStone Presented Preclinical Data for Three Novel or Differentiated ADCs at AACR 2026, Including CS5007 (EGFR/HER3)
CStone Announces 2025 Annual Results: Accelerated Expansion of Global Commercial Footprint and Efficient Advancement of Innovation Pipeline 2.0
CStone Updated Clinical Progress and Key Phase I/II Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody)
CStone Announces MHRA Approval in UK for Sugemalimab in Stage III NSCLC